ABBV May 2024 167.500 call
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0100 |
| Strike | 167.50 |
| Expiry date | 2024-05-31 |
| Day's range | 0.0100 - 0.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 294 |
ZacksAbbVie (ABBV) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
ZacksAbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
PR NewswireAbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.
